Monoclonal antibody therapies—bemarituzumab (FGFR2b), zolbetuximab (CLDN18.2), and ramucirumab (VEGFR2)—represent a precision oncology approach targeting key cancer mechanisms: oncogenic signaling, epithelial antigen-driven proliferation, and angiogenesis. This evidence concerns the gene CLDN18 and cancer.